<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-6343</journal-id>
<journal-title><![CDATA[Farmacia Hospitalaria]]></journal-title>
<abbrev-journal-title><![CDATA[Farm Hosp.]]></abbrev-journal-title>
<issn>1130-6343</issn>
<publisher>
<publisher-name><![CDATA[Grupo Aula Médica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-63432022000300003</article-id>
<article-id pub-id-type="doi">10.7399/fh.11729</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies]]></article-title>
<article-title xml:lang="es"><![CDATA[Iniciativas para la mejora del manejo de los pacientes con coagulopatías congénitas por parte de farmacia hospitalaria]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montoro-Ronsano]]></surname>
<given-names><![CDATA[José Bruno]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Poveda-Andrés]]></surname>
<given-names><![CDATA[José Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Romero-Garrido]]></surname>
<given-names><![CDATA[José Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Chicheri Barrena]]></surname>
<given-names><![CDATA[Blanca]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alberto Vella]]></surname>
<given-names><![CDATA[Vincenzo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario Vall d'Hebrón Pharmacy Department ]]></institution>
<addr-line><![CDATA[Barcelona ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario y Politécnico La Fe Pharmacy Department ]]></institution>
<addr-line><![CDATA[Valencia ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Universitario La Paz Pharmacy Department Hemophilia Unit]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,CSL Behring Iberia S. A.  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Universidad Complutense Facultad de Farmacia Departamento de Farmacología]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>46</volume>
<numero>3</numero>
<fpage>109</fpage>
<lpage>115</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-63432022000300003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-63432022000300003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-63432022000300003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: To identify and promote initiatives aimed at improving the management by hospital pharmacists of patients with congenital coagulopathies in the Spanish healthcare context.  Method: A series of initiatives to improve the care of patients with congenital coagulopathies were identified, evaluated, and prioritized by a panel of hospital pharmacists. Prioritization was based on an assessment of each initiative's impact and feasibility on a scale of 1 to 5. Once initiatives were prioritized, those assigned the highest priority were grouped into three action areas.  Results: Seven areas of activity were identified in which the role of hospital pharmacists is key for the management of patients with congenital coagulopathies: coordination with the healthcare team; drug evaluation and selection; dispensing; patient information and education; pharmacotherapeutic follow-up; research and innovation in the field of congenital coagulopathies; and capacity-building and training of hospital pharmacists. Fifteen initiatives were considered a priority, with an average impact score &#8805; 3.8 and a feasibility score &#8805; 3.2. A total of, 29.4% of the prioritized initiatives corresponded to healthcare, 23.5% to patient information and education, 11.8% to drug evaluation and selection, 11.8% to pharmacotherapeutic monitoring, 11.8% to cross-sectional initiatives, 5.9% to dispensing and 5.9% to research and innovation in the field of congenital coagulopathies: In contrast, initiatives related to capacity-building and training were not prioritized.  Conclusions: Three main action areas were proposed based on the initiatives identified as high priority for the management of patients with congenital coagulopathies by a panel of 16 hospital pharmacists. Action areas revolved around specific activities that hospital pharmacy departments can undertake to contribute to improving the healthcare situation in Spain.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Identificar e impulsar iniciativas orientadas a la mejora del manejo de los pacientes con coagulopatías congénitas por parte de farmacia hospitalaria en el contexto sanitario español.  Método: Se identificaron, evaluaron y priorizaron, por parte de un panel de farmacéuticos especialistas en farmacia hospitalaria, iniciativas para la mejora de la atención a los pacientes con coagulopatías congénitas. La priorización se realizó en base a la valoración de su impacto y factibilidad en una escala del 1 al 5. Una vez obtenida la priorización de las iniciativas, las de mayor puntuación se agruparon en tres grandes líneas de actuación.  Resultados: Se identificaron siete áreas de actividad en las que el papel de los farmacéuticos especialistas en farmacia hospitalaria resulta clave para el manejo del paciente con coagulopatías congénitas: coordinación con el equipo asistencial de pacientes con coagulopatías congénitas; evaluación y selección de medicamentos; dispensación; información y formación al paciente; seguimiento farmacoterapéutico; investigación e innovación en estas patologías; formación y capacitación continuada del farmacéutico especialista en farmacia hospitalaria. Se consideraron prioritarias 15 iniciativas por tener una puntuación media de impacto &#8805; 3,8 y factibilidad &#8805; 3,2. Así, el 29,4% de las iniciativas priorizadas pertenecen al ámbito asistencial, el 23,5% a información y formación al paciente, el 11,8% a evaluación y selección de medicamentos, el 11,8% al seguimiento farmacoterapéutico, el 11,8% a iniciativas transversales, el 5,9% a dispensación y el 5,9% a investigación e innovación en el campo de las coagulopatías congénitas, mientras que las iniciativas referentes a la formación y capacitación a profesionales no resultaron priorizadas.  Conclusiones: Se han propuesto tres grandes líneas de actuación basadas en las iniciativas identificadas como altamente prioritarias por un panel de 16 expertos farmacéuticos especialistas en farmacia hospitalaria para el manejo de pacientes con coagulopatías congénitas. Estas iniciativas se basan en acciones concretas y pueden llevarse a cabo desde los servicios de farmacia hospitalaria, por lo que se cree que podrán llegar a tener un impacto real en el contexto sanitario español.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Hereditary blood coagulation disorders]]></kwd>
<kwd lng="en"><![CDATA[Quality of healthcare]]></kwd>
<kwd lng="en"><![CDATA[Pharmaceutical care]]></kwd>
<kwd lng="en"><![CDATA[Hospital pharmacy department]]></kwd>
<kwd lng="es"><![CDATA[Coagulopatías congénitas]]></kwd>
<kwd lng="es"><![CDATA[Calidad asistencial]]></kwd>
<kwd lng="es"><![CDATA[Atención farmacéutica]]></kwd>
<kwd lng="es"><![CDATA[Servicio de farmacia hospitalaria]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Páramo Fernández]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández del Carril]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Calle]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coagulopatías congénitas]]></article-title>
<source><![CDATA[Med]]></source>
<year>2012</year>
<volume>11</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>1353-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez-Yuste]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez Román]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Mingot-Castellano]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Mosteirin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Mareque]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Oyagüez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análisis de costes del tratamiento para pacientes con hemofilia A con inhibidor en España]]></article-title>
<source><![CDATA[Pharmacoeconomics Spanish Res Artic]]></source>
<year>2018</year>
<volume>15</volume>
<numero>1-4</numero>
<issue>1-4</issue>
<page-range>25-34</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Srivastava]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Brewer]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Mauser-Bunschoten]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Key]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Kitchen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Llinas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines for the management of hemophilia]]></article-title>
<source><![CDATA[Haemophilia]]></source>
<year>2013</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>e1-47</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances and innovations in haemophilia treatment]]></article-title>
<source><![CDATA[Nat Rev Drug Discov]]></source>
<year>2018</year>
<volume>17</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>493-508</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peyvandi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Garagiola]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The past and future of haemophilia: diagnosis, treatments, and its complications]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2016</year>
<volume>388</volume>
<numero>10040</numero>
<issue>10040</issue>
<page-range>187-97</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leebeek]]></surname>
<given-names><![CDATA[FWG]]></given-names>
</name>
<name>
<surname><![CDATA[Atiq]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[How I manage severe von Willebrand disease]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2019</year>
<volume>187</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>418-30</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leebeek]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[Eikenboom]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Von Willebrand's Disease]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>375</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2067-80</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Flood]]></surname>
<given-names><![CDATA[VH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in the diagnosis and treatment of Von Willebrand disease]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2017</year>
<volume>130</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2386-91</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muñoz Grass]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Palacios-Espinosa]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Calidad de vida y hemofilia: Una revisión de la literatura]]></article-title>
<source><![CDATA[CES Psicología]]></source>
<year>2015</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>169-91</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morillo-Verdugo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Margusino-Framiñán]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Monte-Boquet]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Morell-Baladrón]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barreda-Hernández]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rey-Piñeiro]]></surname>
<given-names><![CDATA[XM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Posicionamiento de la Sociedad Española de Farmacia Hospitalaria sobre Telefarmacia. Recomendaciones para su implantación y desarrollo]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2020</year>
<volume>44</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>174-81</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calleja Hernández]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Morillo Verdugo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[El modelo CMO en consultas externas de Farmacia Hospitalaria]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Sociedad Española de Farmacia Hospitalaria]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
